Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Ariad Pharmaceuticals ( ARIA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.0%. By the end of trading, Ariad Pharmaceuticals fell $0.30 (-1.6%) to $18.96 on light volume. Throughout the day, 1,401,134 shares of Ariad Pharmaceuticals exchanged hands as compared to its average daily volume of 3,150,300 shares. The stock ranged in price between $18.94-$19.51 after having opened the day at $19.28 as compared to the previous trading day's close of $19.26. Other companies within the Drugs industry that declined today were: ARCA biopharma ( ABIO), down 30.9%, Genvec ( GNVC), down 12.1%, TG Therapeutics ( TGTX), down 11.3% and SurModics ( SRDX), down 7.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals has a market cap of $3.7 billion and is part of the health care sector. Shares are up 3.1% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Ariad Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Affymax ( AFFY), down 14.6%, Immunomedics ( IMMU), down 13.3%, Catalyst Pharmaceutical Partners ( CPRX), down 13.3% and Regulus Therapeutics ( RGLS), down 12.1% , were all gainers within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)